Who are Postop oral orphenadrine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SCOPOLAMINE, Enlon-Plus, Ipratropium/albuterol, Neostigmine + Glycopyrrolate, Neostigmine + Atropine, oxybutynin immediate release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/postop-oral-orphenadrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Postop oral orphenadrine — Competitive Intelligence Brief

Postop oral orphenadrine (Postop oral orphenadrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic muscle relaxant. Area: Pain Management / Musculoskeletal.

marketed Anticholinergic muscle relaxant Muscarinic acetylcholine receptors Pain Management / Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

Postop oral orphenadrine (Postop oral orphenadrine) — AdventHealth. Orphenadrine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce muscle spasms and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Postop oral orphenadrine TARGET	Postop oral orphenadrine	AdventHealth	marketed	Anticholinergic muscle relaxant	Muscarinic acetylcholine receptors
SCOPOLAMINE	SCOPOLAMINE		marketed	Anticholinergic [EPC]	Muscarinic acetylcholine receptors	1979-01-01
Enlon-Plus	Atropine Sulfate	Alcon Labs Inc	marketed	Antimuscarinic agent	Muscarinic acetylcholine receptors	1960-01-01
Ipratropium/albuterol	Ipratropium/albuterol	National Jewish Health	marketed	Combination bronchodilator (anticholinergic + beta-2 agonist)	Muscarinic acetylcholine receptors (ipratropium); beta-2 adrenergic receptor (albuterol)
Neostigmine + Glycopyrrolate	Neostigmine + Glycopyrrolate	Merck Sharp & Dohme LLC	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
Neostigmine + Atropine	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
oxybutynin immediate release	oxybutynin immediate release	Astellas Pharma Inc	marketed	Anticholinergic	Muscarinic acetylcholine receptors (M2 and M3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic muscle relaxant class)

AdventHealth · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Postop oral orphenadrine — Competitive Intelligence Brief. https://druglandscape.com/ci/postop-oral-orphenadrine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab